Abstract:Autoantigen-specific immunotherapy promises effective treatment for devastating tissue specific autoimmune diseases like multiple sclerosis (MS) and type 1 diabetes (T1D). Because activated dendritic cells (DCs) stimulate the differentiation of autoreactive T cells involved in the initiation of autoimmunity, blocking the activation of DCs may be an effective strategy for inhibiting tissue specific autoimmunity. Following this approach, immature DCs were shown to remain inactive after treatment with chimeric fusion proteins composed of the cholera toxin B subunit adjuvant linked to autoantigens like proinsulin (CTB-INS). Mass spectrometer analysis of human DCs treated with CTB-INS suggest that upregulation of the tryptophan catabolic enzyme indoleamine 2, 3-dioxygenase (IDO1) is responsible for inhibiting DC activation thereby resulting in a state of immunological tolerance within the DC. Here we show that the fusion protein CTB-INS inhibits human monocyte derived DC (moDC) activation through stimulation of IDO1 biosynthesis and that the resultant state of DC tolerance can be further enhanced by the presence of residual E. coli lipopolysaccharide (LPS) present in partially purified CTB-INS preparations. Additional experiments showed that LPS enhancement of DC tolerance was dependent upon stimulation of IDO1 biosynthesis. LPS stimulation of increased levels of IDO1 in the DC resulted in increased secretion of kynurenines, tryptophan degradation products known to suppress DC mediated pro-inflammatory T cell differentiation and to stimulate the proliferation of regulatory T cells (Tregs). Further, the presence of LPS in CTB-INS treated DCs stimulated the biosynthesis of costimulatory factors CD80 and CD86 but failed to upregulate maturation factor CD83, suggesting CTB-INS treated DCs may be maintained in a state of semi-activation. While treatment of moDCs with increasing amounts of LPS free CTB-INS was shown to increase DC secretion of the anti-inflammatory cytokine IL-10, the presence of residual LPS in partially purified CTB-INS preparations dramatically increased IL-10 secretion, suggesting that CTB-INS may enhance DC mediated immunological tolerance by stimulating the proliferation of anti-inflammatory T cells. While the extraction of LPS from bacterial generated CTB-INS may remove additional unknown factors that may contribute to the regulation of IDO1 levels, together, our experimental data suggest that LPS stimulates the ability of CTB-INS to induce IDO1 and IL-10 important factors required for establishment of a state of functional immunological tolerance in human DCs. Regulation of the ratio of LPS to CTB-INS may prove to be an effective method for optimization of readily available "off the shelf" CTB-INS mediated immune-therapy for tissue specific autoimmune diseases including type 1 diabetes.

LPS-treated Bone Marrow-Derived Dendritic Cells Induce Immune Tolerance Through Modulating Differentiation of CD4+ Regulatory T Cell Subpopulations Mediated by 3G11 and CD127.

Distinct Role of IL-27 in Immature and LPS-Induced Mature Dendritic Cell-Mediated Development of CD4+ CD127+3G11+ Regulatory T Cell Subset

Immune Tolerance Induced by Intravenous Transfer of Immature Dendritic Cells Via Up-Regulating Numbers of Suppressive IL-10+ IFN-γ+-producing CD4+ T Cells

[Bone Marrow-Derived Dendritic Cells Rather Than Spleen-Derived Dendritic Cells Can Generate Regulatory T Cells].

Tolerogenic dendritic cells induced the enrichment of CD4 + Foxp3 + regulatory T cells via TGF-β in mesenteric lymph nodes of murine LPS-induced tolerance model.

Polyclonal Cd4(+)Foxp3(+) Treg Cells Induce Tgfb-Dependent Tolerogenic Dendritic Cells That Suppress Murine Lupus-Like Syndrome.

Apoptotic Cell-Treated Dendritic Cells Induce Immune Tolerance Through Specifically Facilitating Development of CD4+ Effector Memory T Cells (IRC10P.408)

Apoptotic Cell-Treated Dendritic Cells Induce Immune Tolerance by Specifically Inhibiting Development of CD4 + Effector Memory T Cells

Apoptotic Cell-induced Tolerogenic Dendritic Cells Facilitate Development of CD4+ and CD8+ Regulatory T Cell Subsets

Tolerogenic Dendritic Cells Transferring Hyporesponsiveness and Synergizing T Regulatory Cells in Transplant Tolerance

Inhibitory Feedback Loop Between Tolerogenic Dendritic Cells and Regulatory T Cells in Transplant Tolerance

A Role for Anti-Cd45rb Monoclonal Antibody Treatment Upon Dendritic Cells.

Murine Bone Marrow Mesenchymal Stem Cells Cause Mature Dendritic Cells to Promote T‐Cell Tolerance

Blockade of CD40 pathway enhances the induction of immune tolerance by immature dendritic cells genetically modified to express cytotoxic T lymphocyte antigen 4 immunoglobulin.

Tolerogenic dendritic cells differentiation induced by liver X receptors(LXR)originated from mouse bone marrow

LPS enhances CTB-INSULIN induction of IDO1 and IL-10 synthesis in human dendritic cells

Intravenous Transfer of Apoptotic Cell-Treated Dendritic Cells Leads to Immune Tolerance by Blocking Th17 Cell Activity.

TSLP/dendritic cell axis promotes CD4+ T cell tolerance to the gut microbiome

Ability of LPS to regulate expression of tolerance-related molecules on dendritic cells is blocked by IL-10 deficiency (48.18)

Anti-CD(45)RB Monoclonal Antibody Induces Immunologic Toleration by Suppressing Dendritic Cells.

CD11c+CD11b+ Dendritic Cells Play an Important Role in Intravenous Tolerance and the Suppression of Experimental Autoimmune Encephalomyelitis.